Skip to main content

Advertisement

Table 4 Least-squares (LS) mean (SE) change from baseline in prolactin levels (ng/ml) at end point

From: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Variable Placebo, n = 83 Paliperidone palmitate
   234/39 mg, n = 72 234/156 mg, n = 72 234/234 mg, n = 85
Males
   n 56 50 46 60
   Baseline, mean (SD) 31.7 (21.1) 28.7 (21.2) 30.2 (25.2) 28.4 (19.0)
   LS mean (SE) change from baseline -25.0 (4.1) 1.3 (3.9) 0.6 (4.1) 2.6 (3.9)
   P value for LS mean (vs placebo) -- <0.001 <0.001 <0.001
Females
   n 27 22 25 25
   Baseline, mean (SD) 81.8 (50.9) 76.2 (53.0) 85.7 (56.3) 80.0 (67.8)
   LS mean (SE) change from baseline -45.9 (17.1) 17.8 (16.3) 17.8 (16.8) 42.9 (17.9)
   P value for LS mean (vs placebo) -- 0.001 <0.001 <0.001
  1. Each paliperidone palmitate subject received 234 mg of paliperidone palmitate on day 1 and then their assigned dose day 8 and monthly thereafter.